Class Action Lawsuit Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Novavax, Inc. That A Securities Fraud Class Action Lawsuit Has Been Filed on Their Behalf | National News

RADNOR, Pa., January 1, 2022 / PRNewswire / – Law firm Kessler Topaz Meltzer & Check, LLP has announced that a securities class action lawsuit has been filed against Novavax, Inc. (“Novavax”) (NASDAQ: NVAX). The lawsuit charges Novavax with violations of US securities laws, including omissions and fraudulent misrepresentations regarding the company’s business, operations and prospects. As a result of Novavax’s materially misleading statements, Novavax investors have suffered significant losses.

CAN’T YOU WATCH THIS VIDEO? YOU’RE WELCOME CLICK HERE

CLICK HERE TO SUBMIT YOUR NOVAVAX LOSSES

DEADLINES OF THE LEADING APPLICANT: January 11, 2022

SCHOOL LESSON: March 2, 2021 through October 19, 2021

CONTACT A LAWYER TO DISCUSS YOUR RIGHTS:

James Maro, Esq. (484) 270-1453 or Duty free (844) 887-9500 or email at [email protected]

NOVAVAX’S SPECIFIED FAULT BEHAVIOR

Novavax is a biotechnology company developing vaccines against serious infectious diseases, including NVX-CoV2373, a vaccine developed against COVID-19. Prior to March 2021, Novavax announced its plan to finalize its Emergency Use Authorization (“EUA”) applications for NVX-CoV2373 with the US Food and Drug Administration (“FDA”) in the second quarter of 2021.

on March 2, 2021Novavax released a press release stating that the company has potential to file EUAs in the second quarter of 2021 and that sales plans for NVX-CoV2373 and agreements for approximately 200 million doses of NVX-CoV2373 have been entered into and secured. Then, on May 10, 2021“The Washington Post reported that Novavax’s EEA filing” was delayed until June at the earliest due to manufacturing issues, “said four people recently briefed on the company’s plans. Later that day, Novavax participated in a call with investors to discuss its financial results for the first quarter of 2021 and confirmed that it is unlikely to file EUA for NVX-CoV2373 in the US until July 2021 at the earliest (the third quarter of 2021). After this news, Novavax’s share price fell $ 15.50 each per share, or 8.81% to close on $ 160.50 per share May 10, 2021.

Then, on August 5, 2021, Novavax announced that it “[e]expect[s] submit for [EUA] to the [FDA for NVX-CoV2373] in the fourth quarter of 2021[,]”held in the third quarter of 2021. After this news, Novavax’s share price fell $ 46.31 per share, or 19.61% to close on $ 189.89 per share August 6, 2021.

Finally on October 19, 2021, Politico published an article entitled “‘They rushed the process’: The suffering of vaccine manufacturers is hampering the global vaccination campaign.” In the article, Politico pointed out that Novavax’s NVX-CoV2373 vaccine “faces significant hurdles to prove that it can produce a shot that meets regulatory quality standards,” and that Novavax will need until the end of 2022 could be issued and received regulatory approvals and permits to complete its manufacture. After this news, Novavax’s share price fell $ 23.69 per share, or 14.76% to close on $ 136.86 per share October 20, 2021.

WHAT CAN I DO?

Novavax Investors can not later than January 11, 2022, attempt to be appointed as lead class representative by Kessler Topaz Meltzer & Check, LLP, or other legal counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages Novavax investors who have suffered significant losses to contact the company directly for more information.

CLICK HERE SIGN IN IN CASE

Who can be a lead plaintiff?

A lead plaintiff is a representative party who acts on behalf of all class members in the conduct of the dispute. The main plaintiff is usually the investor or small group of investors who have the greatest financial interest and who are also appropriate and typical of the proposed class of investors. The lead plaintiff selects an attorney to represent the lead plaintiff and the group, and those attorneys, if approved by the court, are lead or class plaintiffs. Your ability to participate in a recovery will not be affected by whether or not you wish to be the lead plaintiff.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP

Kessler Topaz Meltzer & Check, LLP pursues class action lawsuits in state and federal courts across the country and worldwide. The company has earned a worldwide reputation for excellence and reclaimed millions of dollars for victims of corporate fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by companies and trustees. Ultimately, we succeeded if the bad guys pay and you get your wealth back. The complaint in this lawsuit was not filed by Kessler Topaz Meltzer & Check, LLP. For more information on Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.

CONTACT:

Kessler Topas Meltzer & Check, LLP

James Maro, Jr., Esq.

280 König-von-Preußen-Strasse

Radnor, PA 19087

(844) 887-9500 (toll free)

[email protected]

View original content to download multimedia: https://www.prnewswire.com/news-releases/class-action-lawsuit-reminder-kessler-topaz-meltzer–check-llp-reminds-investors-of-novavax-inc- that-a-securities-fraud-class-action-lawsuit-has-been-filed-in-your-order-301452198.html

SOURCE Kessler Topaz Meltzer & Check, LLP

Comments are closed.